TRAF6 (TNF Receptor Associated Factor 6)

Mechanistically, MST4 was found to promote tumor necrosis factor receptor-associated factor 6 (TRAF6) autoubiquitination through phosphorylation, a critical event for osteoclast activation. Collectively, these results identify MST4 as a key regulator of osteoclast-mediated bone resorption in osteoporosis, suggesting that targeting the MST4-TRAF6 signaling axis may offer a novel therapeutic strategy to prevent bone loss.

These outcomes regarded CHR as a multi-target neuroprotective agent functioning through a coherent molecular mechanism: (1) suppression of the ZNF460-TRAF6 axis, (2) stabilization of IκBα protein, and (3) consequent inhibition of MLKL activation and oligomerization.

In conclusion, low serum miR-4492 serves as a diagnostic and prognostic biomarker for CAP. miR-4492 mitigated LPS-induced inflammation and cell damage in HBEpCs by targeting TRAF6.

YY1 activates USP19 to promote TRAF6 deubiquitination and its stabilization, thereby enhancing microglial inflammation and M1 polarization that exacerbates depression progression. This axis may provide a novel direction for depression diagnosis and treatment.

Hp infection induces macrophage polarization toward M2 type, inhibits its polarization toward M1 and regulates gastric cancer cell function through the miR-146a-5p/TRAF6 signaling pathway, which in turn propels the development of gastric carcinoma.

Additionally, myeloid differentiation primary-response protein 88 (MYD88), TNF Receptor Associated Factor 6 (TRAF-6) and IL-6 were markedly reduced in the liver by EZE. Collectively, EZE may be a promising candidate in sepsis-related liver injury following further clinical studies.

RA co-treatment (50 mg/kg) significantly reversed all functional, biochemical, and histological damage by strategically breaking this crosstalk, restoring redox homeostasis, and simultaneously restraining both cell death programs. In conclusion, RA protects against IFA nephrotoxicity by targeting the critical inflammation-ferroptosis coupling, positioning it as a highly promising adjuvant candidate for clinical use to mitigate IFA-induced renal injury.

CMG effectively mitigates inflammatory infiltration and renal damage in MRL/lpr mice. Preliminary evidence indicates that this protective effect may be associated with reduced activity of the CD40/NF-κB p65 signalling pathway, along with decreased B-cell activation and complement system activation.

SC administration substantially compromised the normal histology of cardiac tissues. These findings suggest that SC showed cardiotoxic effects therefore, it is imperative to conduct clinical trials to validate these findings in humans.

In the presence of the MVP, transcriptionally induced FSP1 is released from IRF1, leading to its ubiquitination and myristoylation, which enable its recruitment to the plasma membrane, where it functions as an oxidoreductase. These findings define a ferroptosis suppression pathway during IAV infection.

Our findings demonstrate that RPL28 contributes to sorafenib resistance in HCC by upregulating CDC6, contributing to tumor proliferation and drug resistance. The newly identified RPL28-CDC6 axis represents a novel mechanism of resistance and a potential therapeutic target to overcome treatment limitations in HCC.

All together, our findings reveal a novel interferon-independent signalling route through which hypoxia-induced mitochondrial stress activates A3A, directly linking metabolic dysfunction to genome instability. This mechanism involves mitochondrial perturbation as a key driver of APOBEC3-mediated mutagenesis in hypoxic tumours and other diseases associated with mitochondrial stress.